Johnson & Johnson is pumping more money into heart care with a roughly $13 billion deal for Shockwave Medical, which specializes in technology that helps open clogged arteries.
The health care giant said Friday that it will spend $335 in cash for each share of Shockwave. The total deal value includes cash acquired.
The deal has already been approved by the boards of directors from both companies.
Founded in 2009, Shockwave focuses on intravascular lithotripsy technology that uses sonic pressure waves to crack calcium lesions in arteries and restore blood flow. It’s similar to a technique used to break up kidney stones. The soundwave emitters are placed inside angioplasty catheters to reach the calcified areas of the artery.
Shockwave’s technology is used to treat coronary artery and peripheral artery disease.
The company’s revenue jumped 49% last year to $730 million.
Hong Kong to host FIBA 3x3 World Tour Final
Protection efforts lift crested ibis population
China brings opportunities rather than risks to world, expert says
Chinese scientists achieve breakthrough in combating plant cancer
Chinese FM mourns passing of renowned Japanese conductor Seiji Ozawa
Safe, healthy cyberspace key for young people
Egypt trials 1st fleet of electric taxis in New Administrative Capital
China's growth against odds raises world's hopes